Tag
The PIONIR randomized crossover trial demonstrates that a specific Tasty&Healthy diet significantly reduces fecal calprotectin levels, a marker of gut inflammation, in first-degree relatives at high risk for Crohn’s disease, sugge
A study in asymptomatic first-degree relatives of Crohn’s disease patients defines preclinical stages using faecal calprotectin, offering a targeted screening approach to enrich prevention trial cohorts.
This study reveals that TL1A-activated CD4+ T cells drive distinct cellular and molecular changes in the rectal mucosa of Crohn’s disease patients with perianal fistulising disease (PFD), highlighting a novel TL1A-LTα1β2/IL-22 axis in
Childhood exposure to siblings with Crohn’s disease significantly raises disease risk, linked to distinct gut microbiome changes that may drive disease onset through immune modulation.
This study reveals the pivotal role of WISP1 in driving intestinal fibrosis in Crohn’s disease through fibroblast metabolic shifts and cytoskeletal remodeling, suggesting WISP1 neutralization as a novel antifibrotic intervention.
The ENIGMA study reveals altered metabolism of the emulsifier polysorbate-80 and elevated artificial sweeteners in Crohn’s disease, linking these dietary additives to disease activity and potential biomarker development.
The REScUE study compared two ustekinumab dosing intensification regimens after secondary loss of response in Crohn’s disease, finding no superiority of more frequent dosing regarding steroid-free remission at 48 weeks.
This article explores how mucosa-associated microbiota changes after ileal resection in Crohn’s disease correlate with postoperative recurrence, highlighting microbial signatures and dynamic ecosystem changes along the Rutgeerts score.
Rare variants in the BIRC3 gene cause defective regulation of RIPK1 signaling, leading to increased intestinal epithelial cell death and monogenic Crohn’s disease. Targeting RIPK1 offers a promising therapeutic strategy.
Recent multi-omic and clinical evidence suggests that specific fermentable fibers, particularly β-glucan and inulin, significantly reduce Crohn’s Disease risk in high-risk individuals by preserving gut barrier function and modulating
Recent longitudinal and multi-omic studies identify specific fermentable fibers, particularly β-glucan and inulin, as critical factors in reducing Crohn’s disease risk by preserving gut barrier function and modulating the microbiome-i
Higher intake of β-glucan and inulin is linked to a 30% reduction in Crohn’s Disease risk among high-risk individuals, mediated by improved gut barrier function, lower systemic inflammation markers, and specific microbial signatures.
A Danish nationwide study reveals higher genetic risk scores for IBD predict more severe disease courses, including increased surgery rates, stronger medication needs, and worse inflammatory markers in both Crohn’s and ulcerative coli
A breakthrough study identifies epithelial Glutathione peroxidase 4 (GPX4) deficiency as a potent predictor of Crohn’s disease recurrence after surgery. The research links this biomarker to endoplasmic reticulum stress and highlights
A multi-omic study reveals that despite effective immune suppression, Crohn’s disease patients in remission exhibit persistent dietary, microbial, and metabolic abnormalities. This research highlights the critical role of ultraprocess
The ADMIRE CD II Phase 3 trial failed to show a significant benefit of darvadstrocel over placebo for complex perianal fistulas in Crohn’s disease, primarily due to an unexpectedly high remission rate in the placebo-controlled surgica
The CD-HOPE trial reveals that cyclic exclusive enteral nutrition (C-EEN) is superior to daily partial enteral nutrition (PEN) for maintaining drug-free remission in children with Crohn’s disease, providing a critical alternative to long-te
A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving
The LOVE‑CD phase 4 cohort shows vedolizumab yields higher sustained clinical and endoscopic remission and fewer serious adverse events when given early in Crohn’s disease versus later-stage, previously biologic‑exposed disease.
An epigenome-wide study (EPIC‑CD) identified peripheral blood DNA methylation panels that predicted response to vedolizumab and ustekinumab (validated AUC 0.75 each) but failed to predict adalimumab response. Models worked best in biologic‑
